The treatment of advanced colorectal cancer has improved substantially during the past decade with the introduction of new and more effective drugs and advances in our understanding of the disease\'s molecular biology ([@bib3]). However, the balance between improved survival and costs, in terms of toxicity, quality of life and financial, can be difficult. The COIN trial (COntinuous or INtermittent) was developed to conclusively address this issue ([@bib1]). Approximately 1600 patients with advanced colorectal cancer were randomised to receive intermittent *vs* continuous systemic therapy with oxaliplatin and fluoropyrimidine. Although the trial did not show non-inferiority of intermittent compared with continuous chemotherapy for advanced colorectal cancer in terms of overall survival, a subgroup analysis suggests that patients with normal baseline platelet counts could gain the benefits of intermittent chemotherapy without detriment in survival, whereas those with raised baseline platelet counts have impaired survival and quality of life with intermittent chemotherapy, and may do better without a treatment break.

Numerous studies have established that elevated inflammatory markers, such as C-reactive protein, neutrophil/lymphocyte ratio (NLR) and platelet-lymphocyte ratio have been associated with poor outcomes in cancer patients with colorectal cancer ([@bib7]; [@bib4]; [@bib5]). Platelets count and neutrophil lymphocyte ratio are inexpensive markers of host inflammation, and may reflect cytokine activation and more aggressive disease. A recently reported meta-analysis of 100 studies comprising 40 559 patients found NLR \> 4 was associated with poorer OS with hazard ratio for OS of 1.81 (95% CI=1.67--1.97; *P*\<0.001), an effect observed in all disease subgroups, sites, and stages ([@bib6]). Lymphocyte count data was not collected in the COIN trial, however the derived NLR (dNLR) has been shown to possess similar prognostic value ([@bib2]).

The aim of the present correlative analysis was to evaluate whether dNLR could predict the effect of intermittent *vs* continuous first-line oxaliplatin and fluoropyrimidine chemotherapy on overall survival in patients with advanced colorectal cancer.

Materials and methods
=====================

The trial design and eligibility criteria have been reported previously ([@bib1]). The primary objective of the phase 3 MRC COIN study was to assess the effect of pre-planned treatment interruptions in oxaliplatin and fluoropyrimidine combination chemotherapy on overall survival. A second randomisation in the trial assessed the effect of addition of cetuximab to continuous oxaliplatin and fluoropyrimidine combination chemo therapy.

After enrolment, patients were randomly assigned (1) to the control arm of continuous (arm A) or intermittent (arm C) chemotherapy. In arm A treatment was continued until disease progression, development of cumulative toxic effects, or patient choice. Patients on arm C received chemotherapy for 12 weeks, after which treatment was stopped completely and the patients were assessed with imaging every 12 weeks. The same chemotherapy was restarted on progression.

Derived neutrophil/lymphocyte ratio (dNLR) calculation
------------------------------------------------------

White blood cell (WBC) and absolute neutrophil count (ANC) were obtained at patient enrolment. The dNLR was calculated using a formula that was previously shown to have predictive power in cancer patients ([@bib7]; [@bib2]).

Statistical methods
-------------------

All statistical analyses were performed by the Cancer Research UK and University College London Cancer Trials Centre. All randomly assigned patients for whom data on WBC and ANC in patient enrolment were available were included in the analysis. A high dNLR was defined using a cut-off value of 2.2, which was the median dNLR.

Associations were assessed using Kaplan--Meier plots and Cox proportional hazard models. An interaction between dNLR (\<2.22) and treatment allocation was used to assess the difference in treatment effects between the two trial arms. Models were adjusted for the *a priori* factors of treatment arm (standard, intermittent), tumour status (resected, locally recurrent, unresected), number of metastatic sites (0 or 1, 2 or more), CEA at baseline (\<100, ⩾100 mg l^−1^), alkaline phosphatase at baseline (\<100, ⩾100 U l^−1^) and platelet count at baseline (\<400 000 *μ*l^−1^, ⩾400 000 *μ*l^−1^). Factors were excluded from the model when they were missing for more than 10% of the population including CEA. Initial analysis of the association between dNLR and overall survival was performed on the ITT population; all comparisons between treatment groups was performed on both the ITT and the per protocol population, defined as all patients who reached the point where the continuous and intermittent strategies diverged, consistent with the original trial definition. As this was a non-inferiority trial, all comparisons between the treatment groups are reported with 80% confidence intervals, with a boundary of 1.162 used to assess non-inferiority ([@bib1]). Receiver operating characteristic analysis was performed to calculate area under the curve (AUC) using one-year survival as the outcome and baseline dNLR as the test variable.

Statistical analysis was carried out using Stata version 12.1 (College Station, TX, USA).

Results
=======

Population studied
------------------

A total of 1630 patients were assigned to the continuous (*N*=815) or intermittent (*N*=815) arms. There was incomplete data for 32 patients (*N*=8 for missing dates, *N*=55 for missing platelets, *N*=1313 for missing dNLR) who were excluded, resulting in a cohort of 1604 patients (accounting for 98.4% of the total study population). Of these patients, 971 (60.5%) remained on study beyond 12 weeks and were included in the per protocol analysis ([Table 1](#tbl1){ref-type="table"}).

Prognostic
----------

There was a strong association between dNLR level and overall survival. The median survival times in the ITT population were 18.6 months and 12.5 months for patients with low and high dNLR, respectively (HR=1.70; 95% CI=1.52--1.90; *P*\<0.001). The estimate of the hazard ratio did not alter substantially (HR=1.54) after adjusting for treatment, tumour status, number of metastatic sites, alkaline phosphatase and platelet count ([Figure 1](#fig1){ref-type="fig"}). The AUC was 64.5% and there was a detection rate for survival of 82.5% and a false positive rate of 63.1%. As a comparator, the AUC for platelets was 62.8%, and using a value of 400 000 *μ*l^−1^ to dichotomise baseline platelets there was a detection rate of 76.8% and a false positive rate of 58.8%. Both criteria remain modestly prognostic as previously defined ([@bib8]).

Predictive effect of high dNLR
------------------------------

There was no evidence of a differential effect of treatment between the two dNLR groups in the ITT population only (*P*=0.20). Among patients with low baseline dNLR, the hazard ratio for treatment allocation was 1.16 (80% CI=1.00--1.34) compared to 1.21 (80% CI=1.09--1.34) among the high dNLR group. In the per protocol population (*N*=971), the hazard ratios were 1.06 and 1.26 for the low and high dNLR groups respectively. There was no evidence to support a differential treatment effect in this population (*P*=0.26 for interaction between dNLR group and treatment allocation), nor evidence of non-inferiority ([Figure 2](#fig2){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}).

As previously reported, a raised platelet count at baseline (⩾400 000 *μ*l^−1^, recorded for 271 (28%) of 978 patients) predicts a significant survival detriment from intermittent chemotherapy (*P*=0.0027 for interaction). Combining platelet count and dNLR as a single predictive factor was not superior to platelet count alone ([Supplementary Table 1](#sup1){ref-type="supplementary-material"}).

Discussion
==========

We demonstrate that dNLR is prognostic in the COIN intermittent *vs* continuous comparison but does not add to the platelet count in selecting patients who would benefit from continuous rather than intermittent therapy. Although some cut-off value of ⩾2.2 did select a population who benefited from continuous treatment, such an approach lacks robust statistical process and we have reported an outcome using the median dNLR of 2.2. We also conclude that the interpretation of dNLR and the platelet count as predictive factors is more complex than these numerical values would suggest.

A series of studies have proposed that inflammation-based prognostic systems like neutrophil to lymphocyte ratio and thrombocytosis are associated with poor survival of subjects with cancer. A systematic review of 100 studies comprising 40 559 patient with various solid tumours found NLR was associated with an adverse OS hazard ratio of 1.81 (95% CI=1.67--1.97; *P*\<0.001) ([@bib6]), an effect observed in all disease subgroups, sites, and stages. In the six prospective studies used in the NLR meta-analysis containing patients with metastatic colorectal cancer, there were a total of 1817 patients.

The biological mechanism responsible for a higher dNLR requires further investigation, particularly in the context of clinical studies of ruxolitinib and the checkpoint inhibitors. A platelet count of \>400 remains the most robust criteria by which to select patients for intermittent therapy, and this is being investigated in the FOCUS-4 study (<http://www.focus4trial.org/>). Statistical uncertainties with respect to biomarker cut-off values continue to generate difficulties in the interpretation of prognostic and predictive biomarkers.

In conclusion, both dNLR and platelets counts were prognostic in patients with metastatic colorectal cancer receiving first-line chemotherapy in randomised phase III COIN trial. A high dNLR ⩾2.22 and platelets ⩾400 000 *μ*l^−1^ were associated with shorter survival. However, in contrast to platelet count, a high dNLR failed to predict inferiority of intermittent chemotherapy and cannot be used for clinical decision of which patients can benefit from chemotherapy-free breaks.
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###### Population demographics by dNLR

                                                             **dNLR ⩽ 2.2 (*****N*****=805)**   **dNLR** ⩾ **2.2 (*****N*****=799)**
  ---------------------------------------------------------- ---------------------------------- --------------------------------------
  **Treatment**                                                                                 
  A--Standard chemotherapy                                   391 (48.6)                         408 (51.1)
  C--Intermittent chemotherapy                               414 (51.4)                         391 (48.9)
  Age; median (range)                                        63.8 (18-82)                       63.6 (25-87)
  **Sex**                                                                                       
  Male                                                       538 (66.8)                         499 (62.5)
  Female                                                     267 (33.2)                         300 (37.5)
  **WHO performance status**                                                                    
  0--Normal activity without restriction                     417 (51.8)                         320 (40.1)
  1--Strenuous activity restricted; can do light work        348 (43.2)                         402 (50.3)
  2--Up and about \>50% of waking hours, limited self-care   40 (5.0)                           77 (9.6)
  **Status of primary tumour**                                                                  
  Resected                                                   485 (60.2)                         364 (45.6)
  Local recurrence                                           40 (5.0)                           44 (5.5)
  Unresected/unresectable                                    280 (34.8)                         391 (48.9)
  **Number of metastatic sites**                                                                
  0                                                          5 (0.6)                            8 (1.0)
  1                                                          295 (36.6)                         262 (32.8)
  2                                                          326 (40.5)                         316 (39.5)
  3+                                                         179 (22.2)                         213 (26.7)
  **Liver-only metastases**                                                                     
  No                                                         623 (77.4)                         634 (79.3)
  Yes                                                        182 (22.6)                         165 (20.7)
  **Platelets**                                                                                 
  \<400 000 *μ*l^−1^                                         633 (78.6)                         490 (61.3)
  ⩾400 000 *μ*l^−1^                                          172 (21.4)                         309 (38.7)
  **CEA**                                                                                       
  \<100                                                      402 (65.0)                         319 (50.2)
  ⩾ 100                                                      216 (35.0)                         316 (49.8)
  Missing                                                    187                                164
  **Alkaline phosphatase**                                                                      
  \<300                                                      715 (88.8)                         620 (77.6)
  ⩾300                                                       90 (11.2)                          179 (22.4)
  **Mutations of KRAS, NRAF & BRAF**                                                            
  All wild-type                                              299 (46.9)                         293 (47.7)
  At least one mutation                                      338 (53.1)                         321 (52.3)
  Missing                                                    168                                185
  Included in per-protocol analysis                          519 (64.5)                         452 (56.6)

###### Hazard ratios and median survival times of ITT and per protocol populations by dNLR^**a**^

  **Population**          **Median survival time (Arm A** ***vs*** **Arm C)**  **HR (80% CI)**       ***P*****-value for interaction**
  ---------------------- ----------------------------------------------------- --------------------- -----------------------------------
  **ITT**                                                                                            
  dNLR \<2.2 (*N*=805)                      19.2 *vs* 18.1                     1.04 (0.936--1.163)   0.20
  dNLR ⩾2.2 (*N*=799)                       13.0 *vs* 11.9                     1.21 (1.094--1.335)    
  **Per protocol**                                                                                   
  dNLR \<2.2 (*N*=519)                      21.8 *vs* 21.5                     1.06 (0.921--1.224)   0.26
  dNLR ⩾2.2 (*N*=452)                       16.6 *vs* 15.4                     1.26 (1.099--1.446)    

^a^Adjusted for tumour status, number of metastases, alkaline phosphate and platelet count.
